Literature DB >> 28115521

Platelet Factor 4 Binds to Vascular Proteoglycans and Controls Both Growth Factor Activities and Platelet Activation.

Megan S Lord1, Bill Cheng2, Brooke L Farrugia2, Simon McCarthy3, John M Whitelock2.   

Abstract

Platelet factor 4 (PF4) is produced by platelets with roles in both inflammation and wound healing. PF4 is stored in platelet α-granules bound to the glycosaminoglycan (GAG) chains of serglycin. This study revealed that platelet serglycin is decorated with chondroitin/dermatan sulfate and that PF4 binds to these GAG chains. Additionally, PF4 had a higher affinity for endothelial-derived perlecan heparan sulfate chains than serglycin GAG chains. The binding of PF4 to perlecan was found to inhibit both FGF2 signaling and platelet activation. This study revealed additional insight into the ways in which PF4 interacts with components of the vasculature to modulate cellular events.
© 2017 by The American Society for Biochemistry and Molecular Biology, Inc.

Entities:  

Keywords:  extracellular matrix protein; glycosaminoglycan; heparan sulfate; perlecan; proteoglycan; proteoglycan structure; serglycin

Mesh：

Substances：

Year:  2017        PMID： 28115521      PMCID： PMC5354495          DOI： 10.1074/jbc.M116.760660

Source DB:  PubMed          Journal:  J Biol Chem        ISSN： 0021-9258            Impact factor:   5.157


  41 in total

1.  Cartilage and smooth muscle cell proteoglycans detected by affinity blotting using biotinylated hyaluronan.

Authors:  J Melrose
Journal:  Methods Mol Biol       Date:  2001

2.  Characterization of a neutrophil cell surface glycosaminoglycan that mediates binding of platelet factor 4.

Authors:  F Petersen; E Brandt; U Lindahl; D Spillmann
Journal:  J Biol Chem       Date:  1999-04-30       Impact factor: 5.157

3.  Electrophoretic, biosensor, and bioactivity analyses of perlecans of different cellular origins.

Authors:  S Knox; J Melrose; J Whitelock
Journal:  Proteomics       Date:  2001-12       Impact factor: 3.984

4.  Platelet factor 4 blocks the binding of basic fibroblast growth factor to the receptor and inhibits the spontaneous migration of vascular endothelial cells.

Authors:  Y Sato; M Abe; R Takaki
Journal:  Biochem Biophys Res Commun       Date:  1990-10-30       Impact factor: 3.575

5.  Purification and binding properties of human platelet factor four.

Authors:  R I Handin; H J Cohen
Journal:  J Biol Chem       Date:  1976-07-25       Impact factor: 5.157

6.  Bioengineered human heparin with anticoagulant activity.

Authors:  Megan S Lord; Bill Cheng; Fengying Tang; J Guy Lyons; Jelena Rnjak-Kovacina; John M Whitelock
Journal:  Metab Eng       Date:  2016-07-18       Impact factor: 9.783

7.  The degradation of human endothelial cell-derived perlecan and release of bound basic fibroblast growth factor by stromelysin, collagenase, plasmin, and heparanases.

Authors:  J M Whitelock; A D Murdoch; R V Iozzo; P A Underwood
Journal:  J Biol Chem       Date:  1996-04-26       Impact factor: 5.157

8.  Heparin binding to platelet factor-4. An NMR and site-directed mutagenesis study: arginine residues are crucial for binding.

Authors:  K H Mayo; E Ilyina; V Roongta; M Dundas; J Joseph; C K Lai; T Maione; T J Daly
Journal:  Biochem J       Date:  1995-12-01       Impact factor: 3.857

Review 9.  Serglycin--structure and biology.

Authors:  S O Kolset; H Tveit
Journal:  Cell Mol Life Sci       Date:  2008-04       Impact factor: 9.261

10.  The modulation of platelet and endothelial cell adhesion to vascular graft materials by perlecan.

Authors:  Megan S Lord; Weiyun Yu; Bill Cheng; Anne Simmons; Laura Poole-Warren; John M Whitelock
Journal:  Biomaterials       Date:  2009-06-21       Impact factor: 12.479
View more
  17 in total

1.  Platelet factor 4 is a biomarker for lymphatic-promoted disorders.

Authors:  Wanshu Ma; Hyea Jin Gil; Noelia Escobedo; Alberto Benito-Martín; Pilar Ximénez-Embún; Javier Muñoz; Héctor Peinado; Stanley G Rockson; Guillermo Oliver
Journal:  JCI Insight       Date:  2020-07-09

2.  Platelet Factor 4 Interactions with Short Heparin Oligomers: Implications for Folding and Assembly.

Authors:  Chendi Niu; Yang Yang; Angela Huynh; Ishac Nazy; Igor A Kaltashov
Journal:  Biophys J       Date:  2020-04-21       Impact factor: 4.033

3.  Is citrate theophylline adenosine dipyridamole (CTAD) better than citrate to survey unfractionated heparin treatment? Has delayed centrifugation a real impact on this survey?

Authors:  Paul Billoir; Thomas Clavier; Arnaud Guilbert; Virginie Barbay; Marie Hélène Chrétien; Marielle Fresel; Caroline Abriou; Christophe Girault; Véronique Le Cam Duchez
Journal:  J Thromb Thrombolysis       Date:  2019-08       Impact factor: 2.300

4.  Optimization of bioengineered heparin/heparan sulfate production for therapeutic applications.

Authors:  Megan S Lord; MoonSun Jung; John M Whitelock
Journal:  Bioengineered       Date:  2017-04-10       Impact factor: 3.269

5.  A glycan-based approach to cell characterization and isolation: Hematopoiesis as a paradigm.

Authors:  Richard T Piszczatowski; Emily Schwenger; Sriram Sundaravel; Catarina M Stein; Yang Liu; Pamela Stanley; Amit Verma; Deyou Zheng; Ronald D Seidel; Steven C Almo; Robert A Townley; Hannes E Bülow; Ulrich Steidl
Journal:  J Exp Med       Date:  2022-09-06       Impact factor: 17.579

6.  Leukocyte integrin Mac-1 (CD11b/CD18, αMβ2, CR3) acts as a functional receptor for platelet factor 4.

Authors:  Valeryi K Lishko; Valentin P Yakubenko; Tatiana P Ugarova; Nataly P Podolnikova
Journal:  J Biol Chem       Date:  2018-03-14       Impact factor: 5.157

Review 7.  What Are the Potential Roles of Nuclear Perlecan and Other Heparan Sulphate Proteoglycans in the Normal and Malignant Phenotype.

Authors:  Anthony J Hayes; James Melrose
Journal:  Int J Mol Sci       Date:  2021-04-23       Impact factor: 5.923

8.  Anticoagulant Activities of Indobufen, an Antiplatelet Drug.

Authors:  Jia Liu; Dan Xu; Nian Xia; Kai Hou; Shijie Chen; Yu Wang; Yunman Li
Journal:  Molecules       Date:  2018-06-15       Impact factor: 4.411

Review 9.  Platelets in Healthy and Disease States: From Biomarkers Discovery to Drug Targets Identification by Proteomics.

Authors:  Erica Gianazza; Maura Brioschi; Roberta Baetta; Alice Mallia; Cristina Banfi; Elena Tremoli
Journal:  Int J Mol Sci       Date:  2020-06-25       Impact factor: 5.923

10.  Clinical Assay for the Early Detection of Colorectal Cancer Using Mass Spectrometric Wheat Germ Agglutinin Multiple Reaction Monitoring.

Authors:  I-Jung Tsai; Emily Chia-Yu Su; I-Lin Tsai; Ching-Yu Lin
Journal:  Cancers (Basel)       Date:  2021-05-02       Impact factor: 6.639
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.